NMDAR2A/GRIN2A Recombinant monoclonal antibody proteintech 83465-2-RR

$449.00
In stock
SKU
83465-2-RR

 

GRIN2A, NMDAR2A, 240445D4, glun2a, Glutamate [NMDA] receptor subunit epsilon-1

Host / Isotype: Rabbit / IgG Class: Antibody
Reactivity: human, mouse, rat Immunogen: glutamate receptor, ionotropic, N-methyl D-aspartate 2A
 Applications: WB, IF-P, FC (Intra), ELISA Observed Molecular Weight: 160-180 kDa
Formulation: PBS, Azide, Glycerol GenBank Accession Number: GRIN2A
Conjugate: Unconjugated Gene Symbol: 2903
Tested Applications: Positive WB detected in Gene ID (NCBI): AB_3671095
Application: Western Blot (WB) RRID: Unconjugated
Dilution: WB : 1:5000-1:50000 Conjugate: Liquid
Tested Reactivity: Human, Mouse, Rat Form: Protein A purification
Host / Isotype: Recombinant Background Information: GRIN2A (glutamate ionotropic receptor NMDA type subunit 2A), also known as NMDAR2A. And its molecular weight is 165 kDa. GRIN2A is located in cell projection, dendritic spine, cell membrane, synapse, postsynaptic cell membrae, cytolamic vesicle membrane, which is expressed in many tissues, highest expression in brain and heart. This gene encodes a member of the glutamate-gated ion channel protein family. The encoded protein is an N-methyl-D-aspartate (NMDA) receptor subunit. NMDA receptors are both ligand-gated and voltage-dependent, and are involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. These receptors are permeable to calcium ions, and activation results in a calcium influx into post-synaptic cells, which results in the activation of several signaling cascades. Disruption of this gene is associated with focal epilepsy and speech disorder with or without cognitive disability. Alternative splicing results in multiple transcript variants.

 

 

Reviews

Write Your Own Review
You're reviewing:NMDAR2A/GRIN2A Recombinant monoclonal antibody proteintech 83465-2-RR
Your Rating
Copyright © 2025 Biogege, Inc. All rights reserved.